Additional file 3: of Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusionâdependent anemia and thrombocytopenia
Guillermo Garcia-Manero
Antonio Almeida
Aristoteles Giagounidis
Uwe Platzbecker
Regina Garcia
Maria Voso
Stephen Larsen
David Valcarcel
Lewis Silverman
Barry Skikne
Valeria Santini
10.6084/m9.figshare.c.3610133_D2.v1
https://springernature.figshare.com/articles/journal_contribution/Additional_file_3_of_Design_and_rationale_of_the_QUAZAR_Lower-Risk_MDS_AZA-MDS-003_trial_a_randomized_phase_3_study_of_CC-486_oral_azacitidine_plus_best_supportive_care_vs_placebo_plus_best_supportive_care_in_patients_with_IPSS_lower-risk_myelodysplastic_/4359761
Supplementary Appendix for Protocol AZA-MDS-003, Amendment number 2.0, (08 Oct 2015). (DOCX 39Â kb)
2016-05-03 05:00:00
Myelodysplastic syndromes
MDS
IPSS lower risk
CC-486
Azacitidine
Red blood cell transfusion dependence
Anemia
Thrombocytopenia